

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 December 2024 (26.12.2024)



(10) International Publication Number
WO 2024/261329 A1

(51) International Patent Classification:

A61K 31/437 (2006.01) A61P 25/28 (2006.01)
A61K 31/498 (2006.01) A61P 29/00 (2006.01)
A61K 31/4985 (2006.01) A61P 35/00 (2006.01)
A61P 9/00 (2006.01) A61P 37/00 (2006.01)
A61P 25/04 (2006.01)

(21) International Application Number:

PCT/EP2024/067567

(22) International Filing Date:

21 June 2024 (21.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23180701.7 21 June 2023 (21.06.2023) EP

(71) Applicant: **AUGUSTINE THERAPEUTICS** [BE/BE];
Gaston Geenslaan 3, 3001 Leuven (BE).

(72) Inventors: **CELANIRE, Sylvain**; c/o Augustine Therapeutics, Bio-Incubator Leuven, Gaston Geenslaan 3, 3001 Leuven (BE). **ROMBOUTS, Frederik Jan Rita**; c/o Augustine Therapeutics, Bio-Incubator Leuven, Gaston Geenslaan 3, 3001 Leuven (BE). **SENNIENN, Peter Christian**; Franz-Joseph-Str. 7, 80801 Munich (DE).

(74) Agent: **ICOSA EUROPE**; Rue d'Oultremont, 37, 1040 Bruxelles (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS



(57) Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein Y¹ is a 9- or 10-membered bicyclic heteroaryl, Y² is a 5- or 6-membered heteroaryl or 6-membered aryl, L is a linker, Z^{1'} is selected from -NR^{23'} R^{24'} and -(C₃-C₇) heterocyclo alkyl comprising at least one nitrogen atom, and R^{23'} and R^{24'} may be various groups. The present invention further relates to a compound of formula (I) as HDAC6 inhibitor, typically for use in the treatment and/or the prevention of an HDAC6-associated disease, such as cancers, neurodegenerative diseases, neuropathies, cardiovascular diseases, or metabolic or hormonal disorders.



WO 2024/261329 A1